BMS-191095

• Description:

  BMS-191095 is a selective activator of mitochondrial ATP-sensitive potassium (mitoKATP) channels. BMS-191095 inhibits human platelet aggregation by opening mitochondrial K (ATP) channels[1][2][3].

• UNSPSC:

  12352005

• Target:

  Potassium Channel

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Neurological Disease; Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/BMS-191095.html

• Purity:

  98.01

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  CC(O1)(C)[C@H](O)[C@@H](N(CC2=NC=CN2)C3=CC=C(Cl)C=C3)C4=C1C=CC(C#N)=C4

• Molecular Formula:

  C22H21ClN4O2

• Molecular Weight:

  408.88

• References & Citations:

  [1]Katakam PV, et al. Diversity of mitochondria-dependent dilator mechanisms in vascular smooth muscle of cerebral arteries from normal and insulin-resistant rats. Am J Physiol Heart Circ Physiol. 2014 Aug 15;307 (4) :H493-503.|[2]Cho MR, et al. BMS-191095, a cardioselective mitochondrial K (ATP) opener, inhibits human platelet aggregation by opening mitochondrial K (ATP) channels. Arch Pharm Res. 2005 Jan;28 (1) :61-7.|[3]Mayanagi K, et al. The mitochondrial K (ATP) channel opener BMS-191095 reduces neuronal damage after transient focal cerebral ischemia in rats. J Cereb Blood Flow Metab. 2007 Feb;27 (2) :348-55.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 1

• CAS Number:

  [166095-21-2]